Advances

FDA approved nusinersen (Spinraza, Biogen), the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

A recent study found that the compound, NMN, boosts production of NAD+ in mice and could have anti-aging effects along with additional benefits, but more research is necessary to determine its effect on humans.